TREM2 on microglia serves as a critical receptor for amyloid clearance in Alzheimer's disease. Its genetic variants significantly alter disease progression, making this pathway a key therapeutic target. The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most important genetic risk factors for late-onset Alzheimer's disease, second only to APOE[@deczkowska2020].
TREM2 is a type I transmembrane protein belonging to the immunoglobulin superfamily. The extracellular domain contains a single V-type immunoglobulin domain responsible for ligand binding, while the cytoplasmic tail lacks intrinsic signaling capacity and requires association with the adaptor protein DAP12 (TYROBP) for signal transduction[@ulrich2014]. The receptor is expressed primarily on tissue-resident macrophages, including microglia in the central nervous system, where it functions as a critical sensor of tissue damage and pathological protein aggregates.
The ligand repertoire of TREM2 encompasses a diverse array of molecules, including amyloid-beta (Aβ) oligomers and fibrils, various lipids and lipoproteins, apolipoproteins (particularly APOE), and anionic surfaces[@kong2024]. This broad ligand specificity enables TREM2 to serve as a general sensor of pathological changes in the brain parenchyma. The receptor exhibits particular affinity for Aβ oligomers, which are considered the most synaptotoxic species in AD pathogenesis, suggesting a specialized role in clearance of these harmful aggregates.
TREM2 on microglia serves as a critical receptor for amyloid clearance in Alzheimer's disease. Its genetic variants significantly alter disease progression, making this pathway a key therapeutic target. The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most important genetic risk factors for late-onset Alzheimer's disease, second only to APOE[@deczkowska2020].
TREM2 is a type I transmembrane protein belonging to the immunoglobulin superfamily. The extracellular domain contains a single V-type immunoglobulin domain responsible for ligand binding, while the cytoplasmic tail lacks intrinsic signaling capacity and requires association with the adaptor protein DAP12 (TYROBP) for signal transduction[@ulrich2014]. The receptor is expressed primarily on tissue-resident macrophages, including microglia in the central nervous system, where it functions as a critical sensor of tissue damage and pathological protein aggregates.
The ligand repertoire of TREM2 encompasses a diverse array of molecules, including amyloid-beta (Aβ) oligomers and fibrils, various lipids and lipoproteins, apolipoproteins (particularly APOE), and anionic surfaces[@kong2024]. This broad ligand specificity enables TREM2 to serve as a general sensor of pathological changes in the brain parenchyma. The receptor exhibits particular affinity for Aβ oligomers, which are considered the most synaptotoxic species in AD pathogenesis, suggesting a specialized role in clearance of these harmful aggregates.
Soluble TREM2 (sTREM2) is generated through proteolytic cleavage by ADAM10 and ADAM17 proteases, releasing the extracellular domain into the cerebrospinal fluid and interstitial fluid[@xia2023]. sTREM2 appears to have complex biology, potentially acting as a decoy that blocks receptor activation or alternatively facilitating microglial survival through poorly understood mechanisms. CSF levels of sTREM2 correlate with disease progression, showing a biphasic pattern with early increases followed by later decreases as disease advances[@mazaheri2019].
Within the brain, TREM2 demonstrates highest expression in microglia, with particularly dense labeling in regions vulnerable to AD pathology including the hippocampus and entorhinal cortex. Single-cell RNA sequencing has revealed that TREM2 expression increases dramatically in disease-associated microglia (DAM) or neurodegenerative microglia that cluster around amyloid plaques[@shi2019]. This upregulation represents a fundamental switch in microglial phenotype, transitioning from a surveilling "homeostatic" state to an "activated" state characterized by enhanced phagocytic capacity and inflammatory responsiveness.
Expression of TREM2 is dynamically regulated by multiple factors. Direct exposure to Aβ stimulates TREM2 transcription through mechanisms involving NF-κB and AP-1 transcription factors[@huang2021]. Inflammatory cytokines including IL-6 and TNF-α also enhance TREM2 expression, creating a feedforward loop where initial Aβ binding triggers inflammatory responses that further increase receptor expression. Paradoxically, chronic exposure to inflammatory stimuli can eventually suppress TREM2, potentially contributing to microglial dysfunction in advanced disease stages.
Upon ligand binding, TREM2 clusters and recruits the adaptor protein DAP12, which contains an immunoreceptor tyrosine-based activation motif (ITAM). DAP12 becomes phosphorylated on tyrosine residues by Src family kinases, creating docking sites for SYK kinase[@wang2020]. SYK recruitment and activation represents the central signaling event downstream of TREM2, initiating multiple downstream cascades that collectively regulate microglial survival, proliferation, and phagocytic function.
The PI3K/Akt pathway represents one of the most critical downstream signaling cascades activated by TREM2. Activation of this pathway promotes microglial survival through multiple mechanisms, including phosphorylation and inactivation of pro-apoptotic proteins such as BAD, activation of mTOR signaling to support protein synthesis and metabolic fitness, and upregulation of anti-oxidant defenses[@lee2018]. TREM2-mediated survival signaling is particularly important in the challenging environment surrounding amyloid plaques, where microglia face significant metabolic and inflammatory stresses.
TREM2 activation triggers phospholipase C-gamma (PLCγ) activity, leading to generation of inositol trisphosphate (IP3) and subsequent calcium release from intracellular stores[@wang2020]. The resulting calcium transient activates calcineurin and other calcium-dependent enzymes that regulate the actin cytoskeleton remodeling necessary for phagocytosis. This pathway also activates PKC isoforms that phosphorylate components of the phagocytic machinery, enhancing the efficiency of Aβ uptake.
The ERK/MAPK pathway downstream of TREM2 promotes microglial proliferation, enabling expansion of the microglial pool in response to pathological challenges[@parhizkar2019]. This expansion is essential for adequate coverage of amyloid plaques and efficient clearance of pathological debris. However, dysregulated proliferation can contribute to neuroinflammation, highlighting the importance of balanced signaling.
TREM2 signaling also activates NF-κB, leading to transcription of inflammatory mediators including cytokines (IL-1β, IL-6, TNF-α), chemokines (CCL2, CXCL10), and complement components[@zhao2020]. This inflammatory response is double-edged: it recruits additional microglia and activates protective responses, but chronic activation contributes to neuronal damage. The balance between these outcomes depends on the strength and duration of TREM2 signaling.
TREM2 directly binds to Aβ oligomers and fibrils through its immunoglobulin domain, with affinity varying based on Aβ aggregation state and the specific TREM2 variant[@kong2024]. Lipid metabolism products, particularly those generated during neurodegeneration, enhance TREM2-Aβ interaction by providing additional binding surfaces and conformational stabilization. This lipid co-operation explains why TREM2 function is particularly important in the context of APOE and other lipid-binding proteins[@song2022].
The efficiency of Aβ uptake by TREM2-expressing microglia depends on multiple factors. Receptor clustering at the cell surface amplifies binding avidity, while actin-driven membrane ruffling and phagosome formation facilitate internalization. The actin nucleation-promoting protein Vav family, downstream of SYK, plays a critical role in remodeling the cytoskeleton for efficient particle engulfment[@yuan2016].
Following internalization, Aβ-containing phagosomes mature through fusion with lysosomes, where acid hydrolases degrade the cargo. TREM2-mediated phagocytosis engages the autophagy-lysosomal pathway, with TREM2 signaling promoting lysosomal function and acidification[@cataldo2016]. Defects in this degradation step can lead to accumulation of undegraded material and lysosomal dysfunction, which has been observed in microglia from AD patients with TREM2 risk variants.
TREM2 also participates in antigen presentation, with processed Aβ peptides loaded onto MHC-II molecules and presented to T cells. This raises the possibility that Aβ-specific T cell responses may be modulated by TREM2 function, though the significance for AD pathogenesis remains unclear.
One important function of TREM2-activated microglia is plaque compaction. Microglial processes physically surround amyloid plaques, forming a barrier that limits diffusion of toxic Aβ species into the surrounding neuropil[@chen2023]. This "coring" behavior involves extension of cellular processes that penetrate and compress the plaque, converting diffuse deposits into more compact structures. Plaque compaction correlates with reduced neuritic dystrophy and may represent a protective response, though its overall impact on cognitive outcomes remains debated.
The TREM2 R47H variant (rs75932628) represents the strongest genetic risk factor for late-onset AD after APOE, approximately tripling disease risk in heterozygous carriers[@cataldo2016]. This variant impairs ligand binding to Aβ, lipids, and APOE, reducing the efficiency of TREM2-mediated phagocytosis and signaling. Carriers of R47H demonstrate increased amyloid burden but paradoxically slower cognitive decline, suggesting that impaired microglial responses may alter the nature of amyloid pathology in ways that affect clinical progression.
The R62H variant (rs143332484) confers moderate AD risk, with estimates suggesting approximately 1.5-fold increased risk. This variant affects TREM2 function through different mechanisms than R47H, potentially altering receptor trafficking or stability rather than direct ligand binding[@schott2023]. The H157Y variant has been associated with earlier age of onset in some populations, while the Y38C variant appears to disrupt receptor expression through misfolding and degradation.
The TREM2 A228T variant (rs2234255) has been associated with reduced AD risk in some studies, though findings have been inconsistent. This variant appears to enhance receptor function, potentially through effects on protein stability or ligand interaction[@gao2022]. Additional protective variants continue to be identified through large-scale genetic studies, providing insights into the structure-function relationships of TREM2.
TREM2 variants show different frequency distributions across populations. The R47H variant is relatively common in European populations (approximately 0.3% allele frequency) but virtually absent in East Asian and African populations[@gao2022]. This population-specific pattern has implications for understanding disease mechanisms and designing therapeutic approaches that will be effective across diverse populations.
Multiple TREM2-activating antibodies have entered clinical development. AL002 (Alector) is a monoclonal antibody that binds to the TREM2 extracellular domain, promoting receptor clustering and downstream signaling. Phase 1 and 2 trials demonstrated acceptable safety and biomarker evidence of target engagement, including dose-dependent increases in CSF sTREM2[@chen2024]. PY314 (Pyramid Biosciences) represents another agonistic antibody in development, with Phase 1 trials initiated in 2024.
Small molecule TREM2 agonists offer advantages including better brain penetration and oral bioavailability, though development has been challenging due to the difficulty of identifying drug-like molecules that engage this protein-protein interaction interface. Peptide-based approaches and engineered TREM2 variants represent alternative strategies under investigation.
Soluble TREM2 has emerged as an independent therapeutic target. Approaches under investigation include recombinant sTREM2 administration, gene therapy to increase sTREM2 production, and protease inhibition to reduce cleavage of membrane-bound TREM2[@xia2023]. The dual nature of sTREM2 (potentially both beneficial and detrimental) adds complexity to this strategy, requiring careful characterization of the optimal isoform and dosing regimen.
AAV-mediated TREM2 expression represents a long-term strategy for enhancing microglial function. Preclinical studies in mouse models have demonstrated that viral delivery of TREM2 can increase microglial coverage of plaques and improve cognitive outcomes. CRISPR-based approaches to directly correct risk variants in patients represent a more futuristic approach, though significant challenges remain in achieving efficient delivery to the brain.
Given the complexity of AD pathogenesis, TREM2-targeted therapies may prove most effective in combination with other approaches. Combinations with anti-amyloid antibodies (lecanemab, donanemab) could enhance microglial clearance of antibody-opsonized Aβ. Combination with APOE-modulating therapies addresses the important interaction between these two major AD risk factors[@evans2023].
CSF and plasma biomarkers of TREM2 function are being developed for patient selection and response monitoring. sTREM2 levels in CSF show characteristic changes during disease progression, with early increases reflecting microglial activation followed by later decreases as microglial function declines[@xia2023]. Genetic variants that affect TREM2 expression influence these biomarker levels, requiring careful interpretation in clinical trials.
PET imaging of microglial activation using TSPO ligands has revealed that TREM2 genetic variants influence the inflammatory response to amyloid pathology. Carriers of risk variants show altered microglial activation patterns, potentially reflecting impaired functional responses. These imaging biomarkers may help identify patients most likely to benefit from TREM2-targeted interventions.
Several TREM2-targeted therapies have completed or are currently undergoing clinical testing. The Phase 1 study of AL002 demonstrated safety and biomarker engagement, with Phase 2 studies ongoing in early AD patients. Additional programs are expected to enter clinical development over the coming years, potentially transforming the therapeutic landscape for AD.
Key questions remain regarding TREM2 function in human disease. The relative importance of different ligand species, the precise mechanisms linking signaling to functional outcomes, and the reasons for the paradoxical effects of TREM2 variants on different disease aspects all require further investigation. Human iPSC-derived microglia and organoid systems offer new opportunities to study TREM2 in human cells.
Understanding why some patients fail to respond to TREM2-targeted therapies will be essential. Potential mechanisms include downstream signaling defects, overwhelming pathology that exceeds microglial clearance capacity, and toxic microenvironmental factors that impair microglial function. Biomarker development to identify non-responders early in treatment will be valuable for clinical development.